Literature DB >> 31489321

Are direct-acting antivirals against hepatitis C virus infection not associated with the recurrence of hepatocellular carcinoma?

Masahiro Ogawa1, Tatsuo Kanda1, Mitsuhiko Moriyama1.   

Abstract

Entities:  

Year:  2019        PMID： 31489321      PMCID： PMC6700000          DOI： 10.21037/hbsn.2019.03.19

Source DB:  PubMed          Journal:  Hepatobiliary Surg Nutr        ISSN： 2304-3881            Impact factor:   7.293


× No keyword cloud information.
  12 in total

1.  Prevention of hepatocellular carcinoma recurrence: actuality and perspectives.

Authors:  Tadatoshi Takayama; Masatoshi Makuuchi
Journal:  Hepatogastroenterology       Date:  2002 Jan-Feb

2.  Current management of patients with hepatocellular carcinoma.

Authors:  Tatsuo Kanda; Sadahisa Ogasawara; Tetsuhiro Chiba; Yuki Haga; Masao Omata; Osamu Yokosuka
Journal:  World J Hepatol       Date:  2015-07-28

3.  Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.

Authors:  María Reig; Zoe Mariño; Christie Perelló; Mercedes Iñarrairaegui; Andrea Ribeiro; Sabela Lens; Alba Díaz; Ramón Vilana; Anna Darnell; María Varela; Bruno Sangro; José Luis Calleja; Xavier Forns; Jordi Bruix
Journal:  J Hepatol       Date:  2016-04-13       Impact factor: 25.083

Review 4.  Meta-analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma.

Authors:  A K Singal; D H Freeman; B S Anand
Journal:  Aliment Pharmacol Ther       Date:  2010-10       Impact factor: 8.171

5.  Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals.

Authors:  Fabio Conti; Federica Buonfiglioli; Alessandra Scuteri; Cristina Crespi; Luigi Bolondi; Paolo Caraceni; Francesco Giuseppe Foschi; Marco Lenzi; Giuseppe Mazzella; Gabriella Verucchi; Pietro Andreone; Stefano Brillanti
Journal:  J Hepatol       Date:  2016-06-24       Impact factor: 25.083

6.  Favorable Prognosis in Patients with Sustained Virological Response to Antiviral Therapy, Including Interferon, for Chronic Hepatitis C Before Hepatic Resection for Hepatocellular Carcinoma.

Authors:  Ken Shirabe; Keishi Sugimachi; Noboru Harada; Hiroto Kayashima; Takashi Maeda; Eiji Tsujita; Ryosuke Minagawa; Kiyoshi Kajiyama; Shohei Yoshiya; Yoshihiko Maehara
Journal:  Anticancer Res       Date:  2015-12       Impact factor: 2.480

Review 7.  Interferon-free treatment for HCV-infected patients with decompensated cirrhosis.

Authors:  Tatsuo Kanda
Journal:  Hepatol Int       Date:  2016-06-09       Impact factor: 6.047

8.  Prediction of the very early occurrence of HCC right after DAA therapy for HCV infection.

Authors:  Yoshihiko Ooka; Kanda Miho; Obi Shuntaro; Masato Nakamura; Sadahisa Ogasawara; Eiichiro Suzuki; Shin Yasui; Tetsuhiro Chiba; Makoto Arai; Tatsuo Kanda; Hitoshi Maruyama; Osamu Yokosuka; Naoya Kato; Hitoshi Mochizuki; Masao Omata
Journal:  Hepatol Int       Date:  2018-09-21       Impact factor: 6.047

9.  APASL consensus statements and management algorithms for hepatitis C virus infection.

Authors:  Masao Omata; Tatsuo Kanda; Ming-Lung Yu; Osamu Yokosuka; Seng-Gee Lim; Wasim Jafri; Ryosuke Tateishi; Saeed S Hamid; Wan-Long Chuang; Anuchit Chutaputti; Lai Wei; Jose Sollano; Shiv Kumar Sarin; Jia-Horng Kao; Geoffrey W McCaughan
Journal:  Hepatol Int       Date:  2012-03-01       Impact factor: 9.029

10.  Hepatitis C virus-associated hepatocellular carcinoma after sustained virologic response.

Authors:  Reina Sasaki; Tatsuo Kanda; Naoya Kato; Osamu Yokosuka; Mitsuhiko Moriyama
Journal:  World J Hepatol       Date:  2018-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.